Daniel Faga is the President and CEO of AnaptysBio, Inc., a biotech company known for developing innovative treatments. He has a solid educational background with a B.S. in Engineering and an M.B.A. in Healthcare Management. Faga stepped into the CEO...

Daniel Faga is the President and CEO of AnaptysBio, Inc., a biotech company known for developing innovative treatments. He has a solid educational background with a B.S. in Engineering and an M.B.A. in Healthcare Management. Faga stepped into the CEO role in 2023 after serving as Interim President since March 2022. His experience spans over 20 years in the life sciences sector, where he held positions such as Chief Operating Officer at Mirati Therapeutics and Chief Business Officer at Spark Therapeutics. Under his leadership, AnaptysBio focuses on creating groundbreaking therapies, particularly for inflammation and immune-related conditions. Notably, his compensation package includes a $1.5 million transition bonus, which reflects a strong financial incentive tied to performance metrics.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other AnaptysBio, Inc. CEOs

A

Daniel Faga

Ex-CEO of AnaptysBio, Inc.

Education

MBA from Harvard Business School

Field of Expertise

Healthcare & Life Sciences - Biotechnology

Sector of Economy

Healthcare

Born

November 20, 1977 - 47 years ago

CEO of AnaptysBio, Inc. for

1 year 2 months (Apr 2022 - Jun 2023)

Previous Experience

Chief Operating Officer at Mirati Therapeutics

Rivals

Competitors/colleagues of Daniel Faga

Holdings

See how much did Daniel Faga make over time.

Daniel Faga’s holdings have seen significant fluctuations recently. When he began his role as CEO, the value of his stock holdings in AnaptysBio was around $25.5 million. However, by March 2023, this figure dipped to approximately $17.7 million, indicating a...

Daniel Faga’s holdings have seen significant fluctuations recently. When he began his role as CEO, the value of his stock holdings in AnaptysBio was around $25.5 million. However, by March 2023, this figure dipped to approximately $17.7 million, indicating a volatile market. Over the months, his investments varied, sometimes reaching as high as $24.11 million in October 2022 before stabilizing at around $16.16 million in October 2023. This reflects the day-to-day ups and downs of being involved in a biotech firm where the market can react sharply to clinical trial results and regulatory updates.

Mar 17, 2025

A

shares

ANAB @ $16.51

Total Stock Sold

$3.38M

ANAB

$3.38M

155,806 ANAB shares

What if they kept their stock?

If Daniel Faga didn't sell their stock, today they would have:
Extra ANAB155,806 shares worth $2.27M.
This is -32.99% and $1.12M less than what they got when they sold the stock.

Insider Trading

See recent insider trades of Daniel Faga.

ANAB

$3.29M

ANAB at $22.10/share

Mar 22, 2024

Sale

ANAB

$149.75K

ANAB at $21.81/share

Jan 6, 2024

Sale

ANAB

887,043 shares

ANAB

Mar 21, 2022

Received

Compensation History

See how much did Daniel Faga make over time.

In 2023, Faga's compensation reached approximately $7.46 million, driven largely by his salary of $640,605 and a performance-based bonus of $352,333. His prior year compensation jumped to $24.4 million, due to the significant stock options and bonuses granted as he transitioned into the CEO role. This structure incentives him to align his performance heavily with the success of AnaptysBio, making the company's growth and stock price pivotal to his earnings. The compensation philosophy at AnaptysBio focuses on tying a substantial part of executive compensation to performance metrics, particularly because of its status as a development-stage biotech company.

Year

2023

Total Compensation

$992.94K

Salary

$640.61K

Board Justification

The compensation program is designed to reward executive officers at a level consistent with overall strategic and financial performance, with a significant portion tied to performance metrics and stockholder returns.

Bonus

$352.33K

Board Justification

The annual target cash bonus opportunity of up to 55% of base salary, earned based on the achievement of specified performance goals for 2023.

Other

$0.00

Board Justification

No additional compensation was reported outside of salary and bonus for 2023.

Restricted Stock

$0.00(0 RSU)

Board Justification

No stock was vested in 2023 as the focus is on cash compensation and performance-based bonuses.

Performance Metrics

Performance metrics for the 2023 cash bonus plan included corporate goals related to clinical trials and financial management.

Other AnaptysBio, Inc. CEOs

Here are other CEOs of AnaptysBio, Inc.

Hamza Suria

Ex-CEO of AnaptysBio, Inc.

September 2011 - March 2022

John Doe

CEO of AnaptysBio, Inc.

July 2023 - Present